Navigation Links
Blood Test To Predict Heart Failures

Researchers at Jefferson Medical College had discovered the existence of an enzyme in the blood that acts as a biomarker for conditions that lead to heart failures. Based on their findings they have now successfully developed // a blood test to predict the onset of heart failure in patients with cardiac disease.

Scientists had previously showed that an enzyme called GRK2 or beta-adrenergic kinase (?ARK1) is critically important in heart function. It is increased in failing human hearts and contributes to the loss of the heart’s contractile strength during the development of heart failure. Decreasing or inhibiting the enzyme reversed heart failure in laboratory tests.

In their latest findings, researchers have shown, using tissue samples from heart failure patients, that they could track heart levels of GRK2 in the blood.

The researchers reported their findings July 29 in an online article in advance of print in the European Heart Journal.

In the study, researchers had compared tissue samples from a group of 24 patients in heart failure who needed transplants to 58 patients who were not as sick, though had various stages of left ventricular malfunction. They found that the sicker patients had higher levels of GRK2 in the heart and in the blood.

Researchers feel that in future they would like to eventually perform large human trials to specifically look at levels of GRK2 to see if they can predict responses to drugs such as beta-blockers or other treatments for heart failure.

Researchers have known from animal studies that the expression of GRK2 appears to be regulated by hormones called catecholamines, which include norepinephrine and epinephrine, message-carrying neurotransmitters in the sympathetic nervous system.

In heart failure, the sympathetic nervous system is in overdrive, and levels of these hormones are high. In congestive heart failure, the beta-adrenergic receptor system fai ls to work properly. One of the functions of GRK2 or beta-adrenergic kinase (?ARK1) is to turn off beta-adrenergic receptors.

Source: Newswise
'"/>




Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Blood clots likely in long travel
4. Hemochromatosis Patients Blood is Safe
5. Blood transfusions beneficial after heart attacks
6. Blood Pressure Drug may slow wasting in burn victims
7. Levels Of Blood Proteins May Help Heart Disease Care
8. Blood test may identify ovarian cancer
9. A Blood test for suicide risk?
10. Blood Pressure Drugs maintain muscle strength
11. Blood test diagnoses heart failure in short time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at Moffitt ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in an ... and sleep monitoring solutions for the global scientific community. The company’s new CentrePoint ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Rob Lowe ... and now he has leant his presence to an educational purpose as the host ... one important one being cancer. In a recent episode, the series focuses on thyroid ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to ... rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive open ... resume and wondering if it’s as ready as you are for a new job ...
(Date:4/27/2017)... ... ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including three ... The first new location will open at the corner of 27th and Randolph in ... Drive this fall. And the third location is in the process of being identified. ...
(Date:4/26/2017)... ... April 26, 2017 , ... Intalere, the healthcare ... podcast, “Make Plans for MACRA,” highlighting the impact of the Medicare ... and how physicians and other clinicians are reimbursed for the care they deliver ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... 20, 2017  CVS Pharmacy, the retail division ... new store design to enhance the retail customer ... health-focused products and expanded beauty selections paired with ... discover new offerings. Together with its innovative digital ... the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: